Last reviewed · How we verify
Shigella flexneri 2a 2457T
At a glance
| Generic name | Shigella flexneri 2a 2457T |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Controlled Human Infection Model Challenge/Rechallenge (PHASE1)
- Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine (PHASE2)
- Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa (PHASE2)
- Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb (PHASE2)
- Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |